Established and emerging pharmacological therapies for post-myocardial infarction patients with heart failure: a review of the evidence

L De Luca - Cardiovascular Drugs and Therapy, 2020 - Springer
After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic
events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic …

[PDF][PDF] Post-myocardial Infarction heart failure: a review on management of drug therapies

G Swaroop - Cureus, 2022 - cureus.com
After myocardial infarction (MI), patients are at a greater risk of heart failure. Post-MI patients
with left ventricular systolic dysfunction have a higher risk of mortality or morbidity. Strong …

Pharmacologic therapies across the continuum of left ventricular dysfunction

WT Abraham, BH Greenberg, CW Yancy - The American journal of …, 2008 - Elsevier
Neurohormonal activation and increased sympathetic stimulation are among the factors that
have been linked to the development and progression of left ventricular dysfunction (LVD) …

Therapies to prevent heart failure post-myocardial infarction

KL Thomas, EJ Velazquez - Current Heart Failure Reports, 2005 - Springer
Heart failure (HF) is a common complication of myocardial infarction (MI) that carries a poor
prognosis when present. HF and/or left ventricular systolic dysfunction (LVSD) occur in …

Management of post-myocardial infarction patients with left ventricular systolic dysfunction

M Gheorghiade, GC Fonarow - The American journal of medicine, 2007 - Elsevier
After a myocardial infarction (MI), patients are at risk for reinfarction, heart failure (HF), and
sudden death. This risk is much higher in patients with left ventricular systolic dysfunction …

Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction: a review

J Harrington, MC Petrie, SD Anker, DL Bhatt… - JAMA …, 2022 - jamanetwork.com
Importance Despite advances in cardiac care, patients remain at a high risk of death and the
development of heart failure (HF) following myocardial infarction (MI). These risks are …

Long-term pharmacological management of reduced ejection fraction following acute myocardial infarction: Current status and future prospects

AAI Abel, AL Clark - International Journal of General Medicine, 2021 - Taylor & Francis
Heart failure (HF) with reduced ejection fraction is common following acute myocardial
infarction (MI), and active medical management can have a profound impact on prognosis …

Medical therapy for heart failure caused by ischemic heart disease

IY Elgendy, D Mahtta, CJ Pepine - Circulation research, 2019 - Am Heart Assoc
Patients with heart failure (HF) syndromes have been categorized as those with reduced
ejection fraction (EF) or preserved EF (HFpEF), and ischemia plays a key role in both types …

Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy

J Sackner‐Bernstein - … Indexed and Peer‐Reviewed Journal for …, 2005 - Wiley Online Library
Current guidelines define the standard of care for patients after myocardial infarction (MI),
with particular focus on patients with significant ventricular dysfunction. Inherent in these …

Role of neurohormonal modulators in heart failure with relatively preserved systolic function

JA Rapp, M Gheorghiade - Cardiology clinics, 2008 - Elsevier
Cardiovascular disease remains the leading cause of mortality in the developed world. It is
estimated that 5 million Americans suffer from heart failure (HF), and roughly 550,000 new …